Veronique Lecault - Jun 15, 2021 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role
Chief Operating Officer, Director
Signature
/s/ Tryn Stimart, attorney-in-fact
Stock symbol
ABCL
Transactions as of
Jun 15, 2021
Transactions value $
$63,333
Form type
4
Date filed
6/16/2021, 08:00 PM
Previous filing
Jun 10, 2021
Next filing
Dec 3, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABCL Common Shares Options Exercise $63.3K +333K +33.13% $0.19* 1.34M Jun 15, 2021 Direct F1
holding ABCL Common Shares 7.16M Jun 15, 2021 See Footnote F2
holding ABCL Common Shares 274K Jun 15, 2021 See Footnote F3
holding ABCL Common Shares 61.6K Jun 15, 2021 By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABCL Share Option (right to buy) Options Exercise $0 -333K -33.33% $0.00 667K Jun 15, 2021 Common Shares 333K $0.19 Direct F1, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Per share exercise price has been converted from CAD to USD based on the grant date exchange ratio of CAD $1.333:USD $1.00 for March 23, 2017 as set forth on Bloomberg.
F2 These shares are held by Pacific Swell Capital Corp ("Pacific Swell"). The Reporting Person is a director of Pacific Swell and shares voting and dispositive power with respect to the shares held by Pacific Swell. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of her indirect pecuniary interest therein.
F3 These shares are held by Slomo Family Trust. The Reporting Person is a co-trustee of the Slomo Family Trust. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of her indirect pecuniary interest therein.
F4 The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on November 8, 2020, subject to the Reporting Person's continuous service to the Issuer on each such date.
F5 Expiration date corrected from the date listed on the Form 3 filed on December 11, 2020.